Medlior Publications
March 23, 2021
Insights

Explore a list of all of Medlior’s recent publications including recent Medlior evidence generation publications and recent Medlior RWE publications.

Recent Medlior RWE publications

  • Scory T, Chen G, Farris M, Shih YH, Pinto L, Cowling T. Lipid-lowering therapy patterns and low-density lipoprotein-cholesterol management among patients with acute myocardial infarction in Alberta, Canada. American College of Cardiology (ACC).20/World Congress of Cardiology (WCC) Virtual; March-June 2020; Read More.

  • Chen G, Sharif B, Farris M, Cowling T, Pinto L, Rogoza R, Fairbarin M, Anderson T. Healthcare resource utilization and associated costs among patients with atherosclerotic cardiovascular diseases in Alberta, Canada. Canadian Journal of Cardiology 2020;30(10): S20. Read More.

  • McMillan H, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmuller H. Disease and treatment burden of spinal muscular atrophy on patients and caregivers in Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal Read More.

  • McMillan H, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmuller H. Disease and treatment burden of spinal muscular atrophy on patients and caregivers in Canada. Neuromuscular Disorders 2020; 30(Supplement 1): S100. Neuromuscular Dystrophy Journal  Read More.

  • Chen G, Sharif B, Gerber B, Farris M, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK. A population-based study examining the epidemiologic burden, healthcare resource utilization and costs of spinal muscular atrophy in Alberta, Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal Read More.

  • Chen G, Sharif B, Gerber B, Farris M, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK. A population-based study examining the epidemiologic burden, healthcare resource utilization and costs of spinal muscular atrophy in Alberta, Canada. Neuromuscular Disorders 2020; 30(Supplement 1): S101. Neuromuscular Dystrophy Journal  Read More.

  • Morrison P, Wang G, Estes M, Sharif B, Shaw E, Cowling T, Tay J, Jimenez-Zepeda VH, Far b, Amannejad Y. Toward Standardized Structured Reporting for the Management of Multiple Myeloma in Alberta: Insights in Application of Machine Learning. Presented at the 2020 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium (e-poster Gallery). Read more and view here.

  • Chen G, Farris M, Cowling T, Colgan SM, Xiang P, Pericleous L, Rogoza RM, Tai M, Anderson T. Treatment and Low-density Lipoprotein Cholesterol management in patients diagnosed with clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology 2019;35(7):884-891. Read More.

  • Chen G, Farris M, Cowling T, Tai M, Pinto L, Colgan S, Rogoza RM, Anderson TJ. Low-density Lipoprotein Cholesterol Management in Patients with Atherosclerotic Cardiovascular Diseases and Pre-existing Diabetes in Alberta, Canada. American Diabetes Association (ADA) 79th Scientific Sessions 2019; June 8, 2019; San Francisco, California. Read more

  • Jimenez-Zepeda VH, Chen G, Cowling T, Shaw E, Farris M, Liu FF, Tay J. Multiple Myeloma Treatment Landscape from 2011 to 2017 in Alberta, Canada: Results from the Population-Based “Identifying Outcomes in Real-World Multiple Myeloma” (INFORMM) Study. Presented at the 24th Congress of the European Hematology Association (EHA); June 13–16, 2019; Amsterdam, Netherlands. Read more.

  • Chen G, Farris M, Cowling T, Colgan S, Xiang P, Pericleous L, Rogoza RM, Tai MH, Anderson TJ. Treatment and Low-density Lipoprotein Cholesterol management in patients diagnosed with clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadain Journal of Cardiology. 2019; 35:7:884-89. Read more

  • Tay J, Chen G, Cowling T, Shaw E, Farris M, Liu F F, Victor H. Jimenez-Zepeda Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study. Accepted for the 2019 ASCO Annual Meeting. Journal of Clinical Oncology 37, 2019 (suppl; abstr e19509) Read more and more.

  • Shaw E, Liu F, Tay J, Jimenez-Zepeda VH, Chen G. Identifying Outcomes in Real-World Multiple Myeloma (INFORMM): Insights in Methodology for Using Administrative Health Data in Alberta. Presented at the 2019 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium; April 14–16, 2019; Edmonton, AB, Canada. Read more and more.

  • Chen G, Farris MS, Cowling T, Colgan S, Xiang P, Pericleous L, Rogoza RM, Anderson TJ. Atherosclerotic Cardiovascular Diseases and Low-Density Lipoprotein Cholesterol Management in Alberta, Canada. Circulation. 2018;138:A142-72 National Journal of Medicine  Read More.

  • Chen G, Farris M, Cowling T. Methodological issues for measuring pharmacotherapy treatment and its calibration with patient outcomes using real-world data. International Journal Population Data Science. 2018; 3:3: 170. Read More.

  • Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Haddad P. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Multiple Sclerosis and Related Disorders 2017; 18(Supplement C): 218-24. Read More.

  • Gerber B, Cowling T, Chen G, Rivest D, Yeung M, Duquette P, Kindudu C, Barbeau M & Haddad P. The Impact of Treatment Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: Real-World Evidence from Alberta, Canada [Abstract]. Value in Health. Nov 2016; 19(7): page A437. National Library of Medicine Read more.

  • Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Schecter R, & Haddad P. MS patient characteristics and healthcare resource utilization from administrative databases: real-world evidence from Alberta, Canada. Presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Sept 2016; London, UK. Read More.

Recent Medlior Evidence Generation publications

  • Nakagawa K, Matsumura K, Scory T, Farris M, Larkin-Kaiser KA, Kikkawa H, Ivanova JI, Wilner KD. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population. Future Oncology. 2020. Read More.

  • Larkin-Kaiser K, Scory T, Farris M, Wilner K, Ivanoa J. PCN14 Updated Network Meta-analysis of First-line EGFR-targeted Tyrosine Kinase Inhibitor Treatments for Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR-activating Mutations. Value in Health. 2020;23(Supplement 1): S24. Read More.

  • Nakagawa K, Matsumura K, Larkin-Kaiser KA, Scory T, Farris M, Kikkawa H, Ivanova J, Wilner K. Indirect Analysis of First-line Tyrosine Kinase Inhibitors for EGFR+ NSCLC in Japanese. 61st Annual Meeting of the Japan Lung Cancer Society 2020; Okayama, Japan. Read More.

  • Hawes S, Harris F, Mubarack D, Hinds T, Cowling C, Waters‐Banker M, Farris M. About‐Setta. Comparative effectiveness and safety, and health‐related quality of life of haemophilia A treatments: A systematic review. (2020), Abstracts. Haemophilia, 26: 27-181. The European Association for Haemophilia and Allied Disorders (EAHAD)  Read More and view on Medlior.

  • Farris M, Larkin-Kaiser KA, Scory T, Boyne D, Wilner KD, Pastel M, Cappelleri JC, Ivanova JI. Network meta-analysis of first-line therapy for advanced EGFR mutation-positive non-small-cell lung cancer: updated overall survival. Future Oncology; Published online 1 Sep 2020. Read More.

  • Larkin-Kaiser K, Waters-Banker C, Cowling T, Snow L.A., Hasani I, Fernet M. Canadian Real-World Evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis: a systematic literature review. Value in Health, Volume 22, S707. Read More.

  • Franek J, Cappelleri JC, Larkin-Kaiser KA, Wilner KD, Sandin R. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncology. 2019;15(24):2857-71. Read more and more.

  • Farris M, White K, Liu FF, Cowling T. A Rapid Literature Review of Real-World Evidence in Multiple Myeloma: Patient Characteristics and Health Outcomes. Presented at The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2018, November 2018; Barcelona, Spain. Read more.

Canadian Agency for Drugs and Technologies in Health (CADTH)

  • Cowling T, Graves E, Loshak H. Canadian Agency for Drugs and Technologies in Health (CADTH) Emerging Health Technology for COVID-19: Virus-neutralizing monoclonal antibodies against SARS-CoV-2. Ottawa: CADTH; 2020 Dec. (CADTH Horizon Scan Report). Read more.

  • Cowling T, Loshak H. An Overview of Liquid Biopsy for Screening and Early Detection of Cancer. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Nov. (CADTH Issues in Emerging Health Technologies; Issue). Read more.

  • Cowling T, Farrah K. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 May (CADTH rapid response report: summary with critical appraisal). Read more.

  • Cowling T, Frey N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults Undergoing Magnetic Resonance Imaging: A Review of Safety Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Mar. (CADTH rapid response report: summary with critical appraisal). Read more.

  • Cowling T, Jones S. Gene therapy: international regulatory and health technology assessment (HTA) activities and reimbursement status. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2018. (Environmental scan; no. 71) Read more.

  • Gerber B, Cowling T, Chen G, & Haddad P. Linking Administrative Data Sets from Alberta, Canada to Examine the Impact of Treatment Adherence on Health Care Resource Utilization Among Multiple Sclerosis Patients. Presented at the 2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, April 2017; Ottawa, Canada. Read More.

  • Cowling T, Dolcine B. Point-of-care testing. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Oct. (Environmental scan; no. 65). Read more

  • Cowling T, Jones S. Topical antibiotics for infected wounds: A review of the clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Mar. (CADTH rapid response report: summary with critical appraisal). Read more.

  • Pant S, Cowling T, Chelak K, Kaunelis D. Opioid formulations with tamper-resistance or abuse-deterrent features — products and policies. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017. (Environmental scan; no. 62). Read more.

  • Cowling T, Boucher M. (2016). Environmental Scan on Pharmaceuticals Requiring Companion Diagnostics. International Journal of Technology Assessment in Health Care. 32(5), 327-336. Read more.

  • Cowling T, Pant S. Single drug technology assessment processes across health technology assessment organizations. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2016 Nov. (Environmental Scan; Issue 55). Read more.

  • Loorand-Stiver L, Cowling T, Perras C. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Ottawa; Canadian Agency for Drugs and Technologies in Health (CADTH); 2013 Oct [updated 2016 Feb]. (Environmental scan; issue 42). Read more.

  • Cowling T, de Léséleuc L. Surgical interventions performed outside the hospital operating room. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2015. (Environmental Scan; Issue 49). Read more.

  • Cowling T, de Léséleuc L. Reprocessing of single-use medical devices: a 2015 update. [Environmental Scan; Issue 48]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015. Read more.

 

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]